一週打一次的incretin mimetics+metofrmin,比januvia/actos都好,還可減肥
Once-Weekly Exenatide vs. Sitagliptin or Pioglitazone for Type 2 Diabetes Long-acting exenatide lowered glycosylated hemoglobin levels more than the other two drugs did. In patients with type 2 diabetes, incretin mimetic drugs stimulate glucose-related insulin secretion, attenuate glucagon release, and delay gastric emptying. Glucagon-like peptide-1 (GLP-1) receptor agonists such as the currently available formulation of exenatide (Byetta) require once- or twice-daily injections; a once-weekly subcutaneous formulation of exenatide is under FDA review. The oral dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (Januvia) slows the degradation of endogenous GLP-1. Incretin mimetics are alternatives to sulfonylureas or thiazolidinediones when diabetes is not controlled by metformin alone. With support from the developers of once-weekly exenatide, researchers randomized 491 adults with type 2 diabetes (glycosylated hemoglobin [HbA1c] level, 7.1%–11.0% with stable metformin dosing) to add...